NEW YORK, Oct. 11, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p01009677/Nanoparticles-in-Biotechnology-Dru...

REPORT HIGHLIGHTS

-The global market for nanoparticles in biotechnology, drug development and drug delivery was valued at $17.5 billion in 2011 and should reach nearly $21.6 billion in 2012. Total market value is expected to reach $53.5 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 19.9%.-Drug delivery systems are expected to increase from $11.3 billion in 2012 to $30.9 billion in 2017, a CAGR of 22.2%.-Drug development and formulation should total nearly $9.4 billion in 2012 and nearly $20.5 billion in 2017, a CAGR of 16.9%.

STUDY GOALS AND OBJECTIVES

This study provides a comprehensive analysis of the market for nanoparticles in the life sciences on a global basis.  Particular attention is given to drug development and formulation and the development of new drug delivery systems.  Its aim is to provide a range of information, from detailed product analyses within health and wellness subsegments to overall industry trends in order to quantify and qualify the market for drug products for treating various disease conditions in both men and women.  The applicability of specific types of nanoparticles for specific applications is discussed.

Forecasts and trends are developed from a cross-reference of data points gleaned from proprietary industry sources, company publications, industry benchmarking and other divergent data sources to arrive at a cogent and coordinated forecast.

The nanoparticle drug/delivery market presents an increasingly significant part of the overall pharmaceutical product market worldwide.  This study investigates the specific classes of nanoparticles and the pharmaceutical products associated with them.  Existing drug products and potential drugs in the pipelines of the major pharmaceutical players in this market are reviewed.  Growing health concerns in developing countries are expected to continue to contribute substantially to market growth through the forecast period (2012 through 2017).  This report analyzes emerging markets by technology category.  Continued growth is expected in emerging geographies driven by the health awareness of the growing middle class in emerging countries such as India, China, Brazil and Russia.This report seeks to address the critically important topics of analyzing a changing market dynamic, emerging players and products, strategies for accessing emerging markets and awareness of specific disease prevalence and geographies thereof in order to allocate resources and make effective decisions.

SCOPE OF REPORT

Current and projected product forecasts during the forecast period of 2012 through 2017 are discussed.  New product launches will be discussed.  Revenue figure for 2011 are in an actual figures except where actual results have not been reported due to the timing of this report's release.

The report includes analysis of leading and emerging drug products for each nanoparticle type.  Profiles of manufacturers of leading products and their specific products are provided.  This report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment.  The competitive environment is examined with a special focus on how new products will alter the quality of life of patients receiving nanoparticle-associated drugs.

Market figures are based on revenues at the manufacturer level and are projected at 2011 dollar value.  Inflation is not computed into the projection figures.  Trends are assessed based on projected sales for existing products, for new product introductions, expanded markets for existing products and other factors affecting the market.

Included in this report are forecasts by product, product category and by company from 2010 through 2017.  The study is arranged to offer an overview of existing nanoparticle technology and of drug markets; it is accompanied by nanoproduct, company, geography, and mechanism of action, with forecasts broken down and covered by geographic region or country.

Patent and clinical trial information is reviewed for various candidate nanodrugs.  The status of approvals of drugs in each segment by the FDA and regulatory agencies in other countries is reviewed.Figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change.  Revenue figures do not account for variation in local currencies.All market share data presented is on a global basis unless specifically noted.

INTENDED AUDIENCE

This report is an invaluable tool for business planners, acquisitions specialists, licensing strategists, product managers, market research analysts, investors, investor consultants and anyone interested in the nanoparticle drug market, its products, its industry participants and its future.

The importance of identifying overall market trends, product opportunities, emerging geographies, merger and acquisition (M&A) opportunities and insights that provide guidance for sales growth or defensive moves cannot be overstated for a variety of constituents, including:

Established companies in the industry shall benefit from the contents, including corporate strategy, sales and marketing, business development and R&D.

Emerging players in the segment must understand specific opportunities for out-licensing originating from the elements of differentiation of their product or technology as compared to leading, competitive and emerging products.  As well, market forecasts can support investment provided a thorough and detailed substantiation is provided for the market forecast, as is found in this study.

Investment firms evaluating candidates for venture capital or hedged investments will gain insights as to the opportunities and risks that are being encountered in the industry in a product- and company-specific analysis.Equity analysts are provided detailed forecasts for the next five years, substantiated by quantitative analysis that can support further analysis to product and company forecasts over the short and long run.

METHODOLOGY AND INFORMATION SOURCES

In-depth interviews were conducted with leading experts in the field who are executives in companies, industry analysts, and leading individuals in the field.

The nanoparticle biomedical technology market is comprised of drug products for treatment of an assortment of specific diseases of both men and women.  For completeness, the current and forecasted markets are comprised of the total market opportunity for each respective segment.  Within each subsection there are detailed forecasts for each driving mechanism or relevant area of growth.

Information to prepare this report was obtained from participating and emerging companies in the nanoparticle area and from the National Institute of Kidney and Urologic Diseases Information Clearinghouse (NKUDIC), a service of Nat. Inst. of Diabetes and Digestive and Kidney Diseases (NIDDK), National Library of Medicine (NLM, NIH).  Additional information was obtained from a variety of medical and technical journals in the various specialties of the nanoparticle applications.  Other sources include: the New York Times, Wall Street Journal, Washington Post, other newspapers, company documents and other websites.  Population estimates are based on those reported by the International database of the U.S. Census Bureau.  Statistical data was obtained from the World Health Organization (WHO), National Institute of Health (NIH) and WHO Collaborating Centre for Drug Statistics Methodology (Norway).Current and historical revenue figures for individual products have been sourced from company disclosures that exist in the public domain or from government sources.

ANALYST CREDENTIALS

Jackson Highsmith is a life sciences research consultant with more than 16 years of research experience.  Jackson has been consulting with specialty pharmaceuticals and large pharmaceutical industry players since 2007.   Prior to that, he worked at a large research consultancy where he focused on in-depth research; he also has worked at a large pharmaceutical company in a wide range of medical therapeutics in early- and mid-stage drug development.

STUDY GOALS AND OBJECTIVES 1

REASONS FOR DOING THE STUDY 1

SCOPE OF REPORT 1

INTENDED AUDIENCE 2

METHODOLOGY AND INFORMATION SOURCES 2

ANALYST CREDENTIALS 3

RELATED BCC REPORTS 3

BCC ON-LINE SERVICES 3

DISCLAIMER 4

CHAPTER 2 SUMMARY 6

SUMMARY TABLE GLOBAL MARKET FOR NANOPARTICLES IN BIOTECHNOLOGY AND

PHARMACEUTICALS, THROUGH 2017 ($ MILLIONS) 6

SUMMARY FIGURE GLOBAL MARKET FOR NANOPARTICLES IN BIOTECHNOLOGY AND

PHARMACEUTICALS, 2010-2017 ($ MILLIONS) 7

CHAPTER 3 OVERVIEW 9

NANOPARTICLE OVERVIEW 9

TABLE 1 DESCRIPTION OF NANOPARTICLES USED IN DRUG DELIVERY AND DIAGNOSTIC

IMAGING 10

LIPOSOMES 10

NANOSHELLS 11

QUANTUM DOTS 11

SUPERPARAMAGNETIC NANOPARTICLES 11

DENDRIMERS 11

NANORODS 11

BRIEF HISTORY OF NANOPARTICLES 12

NANOPARTICLES IN BIOTECHNOLOGY 12

TABLE 2 APPLICATION OF NANOPARTICLES IN BIOTECHNOLOGY 13

NANOPARTICLES IN DRUG DEVELOPMENT 13

TABLE 3 APPLICATION OF NANOPARTICLES IN DRUG DEVELOPMENT 14

NANOPARTICLES IN DRUG DELIVERY SYSTEMS 14

TABLE 4 APPLICATION OF NANOPARTICLES IN DRUG DELIVERY SYSTEMS 15

TABLE 5 NANOPARTICLE DRUG DELIVERY SYSTEMS 16

NANOPARTICLES IN DIAGNOSTIC IMAGING 16

TABLE 6 NANOPARTICLES USED FOR IN VIVO DIAGNOSTIC IMAGING 18

MAJOR PLAYERS IN NANOPARTICLE DRUG DELIVERY FIELD 18

TABLE 7 MAJOR PLAYERS IN NANOPARTICLE DRUG FIELD 19

TABLE 8 MAJOR PLAYER COMPANY REVENUES FOR NANOPARTICLE DRUGS, THROUGH

2017 ($ MILLIONS) 20

CHAPTER 4 GLOBAL MARKET FOR NANOPARTICLES IN LIFE SCIENCE 22

TABLE 9 GLOBAL MARKET FOR NANOPARTICLES IN BIOTECHNOLOGY AND

PHARMACEUTICALS, THROUGH 2017 ($ MILLIONS) 22

GLOBAL MARKET FOR NANOPARTICLES IN BIOTECHNOLOGY 22

TABLE 10 GLOBAL REVENUES BIOTECHNOLOGY APPLICATIONS OF NANOPARTICLES,

THROUGH 2017 ($ MILLIONS) 23

GLOBAL MARKET FOR NANOPARTICLES IN DRUG DEVELOPMENT 23

TABLE 11 GLOBAL MARKET FOR NANOPARTICLES IN DRUG DEVELOPMENT AND

FORMULATION, THROUGH 2017 ($ MILLIONS) 24

GLOBAL MARKET FOR NANOPARTICLES IN DRUG DELIVERY SYSTEMS 24

TABLE 12 GLOBAL REVENUES FROM NANOPARTICLES IN DRUG DELIVERY SYSTEMS,

THROUGH 2017 ($ MILLIONS) 25

GLOBAL MARKET FOR NANOPARTICLES IN DIAGNOSTIC IMAGING 25

TABLE 13 GLOBAL REVENUES FROM NANOPARTICLES IN DIAGNOSTIC IMAGING SYSTEMS,

THROUGH 2017 ($ MILLIONS) 25

CHAPTER 5 NANOPARTICLES STRUCTURE 28

ADOPTION OF NANOPARTICLES IN APPLIED MARKETS 28

TABLE 14 NANOPARTICLE STRUCTURE AND PROPERTIES 28

FULLERENES, CARBON TUBES AND BUCKY BALLS 29

LIQUID CRYSTALS 29

LIQUID CARRIERS 29

LIPOSOMES 30

DENDRIMERS 30

CHITOSAN AND ALGINATE 31

NANOCRYSTALS 31

QUANTUM DOTS 32

SUPERPARAMAGNETIC NANOPARTICLES 32

CHAPTER 6 NANOPARTICLE PRODUCTION 35

METHOD OF NANOPARTICLE FORMATION 35

SELF-ASSEMBLY PRODUCTION 36

METHODS OF STABILIZATION 37

METHODS OF DRUG INTRODUCTION 37

POLYMERIC NANOPARTICLES 37

MICELLES 38

LIPOSOMES 38

TABLE 15 SAMPLE OF DRUGS DELIVERED THROUGH LIPOSOME NANOTECHNOLOGY 39

GOLD AND SILICON NANOPARTICLES 39

DENDRIMERS 40

METHODS OF LOADING BIOLOGICAL MOLECULES INTO NANOPARTICLES 40

NANOCRYSTAL DRUGS 41

TABLE 16 APPROVED NANOCRYSTAL DRUGS 42

PROBLEM WITH LARGE-SCALE NANOPARTICLE PRODUCTION 42

CHAPTER 7 NANOPARTICLES IN BIOTECHNOLOGY 45

TABLE 17 NANOPARTICLES IN BIOTECHNOLOGY APPLICATIONS 45

RESEARCH AND DEVELOPMENT 45

STEM CELL RESEARCH 46

CELLULAR REPAIR 47

IN VITRO IMAGING 48

PARAMAGNETIC AND SUPERPARAMAGNETIC NANOPARTICLES 49

BIOSENSORS AND QUANTUM DOTS 49

QUANTUM DOTS 49

BIOSENSORS 50

TABLE 18 NANOBIOSENSOR TECHNOLOGY UNDER DEVELOPMENT 51

CHAPTER 8 NANOPARTICLES IN DRUG DEVELOPMENT AND FORMULATION 53

TABLE 19 NANOPARTICLES IN DRUG DEVELOPMENT APPLICATIONS 53

BIOSEPARATIONS 53

TABLE 20 MONOCLONAL ANTIBODY (MAB) DRUGS WITH POTENTIAL FOR USE IN

NANOPARTICLE DELIVERY SYSTEMS 54

RAPID DRUG ANALYSIS 57

REMOVAL OF IMPURITIES AND TOXINS 57

USING NANOPARTICLES TO INCORPORATE INSOLUBLE DRUGS 58

TABLE 21 SOLID LIPID NANOPARTICLE-REFORMATTED DRUGS 59

SCREENING/PROFILING DRUG CANDIDATES 59

COMBINING ANTIBODIES AND DRUGS INTO NANOPARTICLES 60

GOLD AND SILVER NANOPARTICLES IN BIOMEDICINE 60

DNA NANOPARTICLE DEVELOPMENT OF DNA-SPECIFIC DRUGS 62

CHAPTER 9 NANOPARTICLES IN DRUG DELIVERY SYSTEMS 66

NANOPARTICLES IN DRUG DELIVERY APPLICATIONS 66

TABLE 22 NANOPARTICLES IN DRUG DELIVERY APPLICATIONS 66

DESIGNING A NANOPARTICLE DRUG DELIVERY SYSTEM 67

NANOPARTICLE DRUG STABILITY 67

SIZE HOMOGENEITY OF NANOPARTICLE PREPARATIONS 68

DRUG LOADING OF NANOPARTICLES 69

DRUG RELEASE FROM NANOPARTICLE 70

EXTERNAL TRIGGERS FOR RELEASING DRUG FROM NANOPARTICLES 71

BINDING/INCORPORATION OF BIOMOLECULES TO NANOPARTICLES 72

NANOPARTICLE TOXICITY 74

LARGE-SCALE MANUFACTURING 76

METHODS OF ADMINISTRATION OF NANOPARTICLE DRUGS 78

TABLE 23 STANDARD ROUTES OF DRUG ADMINISTRATION 78

ORAL ADMINISTRATION 78

INJECTION ADMINISTRATION 79

TRANSDERMAL PATCH 79

TABLE 24 NANOPARTICLE TRANSDERMAL PATCH PRODUCTS 79

IMPLANTATION ADMINISTRATION 80

INHALATION ADMINISTRATION 81

NANOPARTICLES SUITABLE FOR DRUG DELIVERY SYSTEMS 81

TABLE 25 TYPES OF NANOPARTICLES SUPPLIED IN DRUG DELIVERY SYSTEMS 82

LIPID-BASED NANOPARTICLES 82

NANOCRYSTALS 83

MICELLE NANOPARTICLES 84

DENDRIMERS NANOPARTICLES 84

POLYMERIC NANOPARTICLES 85

METAL-BASED NANOPARTICLES 85

BIOLOGICAL MACROMOLECULAR NANOPARTICLES 87

MESOPOROUS NANOPARTICLES 89

NANOCRYSTALS 90

TABLE 26 NANOCRYSTAL DRUGS APPROVED BY THE FDA 91

NANOPARTICLE DRUG DELIVERY SYSTEM CURRENTLY AVAILABLE 91

ANTIBIOTIC NANOPARTICLES 91

ANTI-TUMOR AND SMALL MOLECULE DELIVERY BY NANOPARTICLE 93

RELEASE OF ANTI-CANCER DRUGS FROM NANOPARTICLES 97

BIOMACROMOLECULES DELIVERED BY NANOPARTICLES 99

NANOPARTICLE COATINGS FOR DRUG DELIVERY SYSTEMS 102

REMOVAL OF NANOPARTICLES FROM THE BODY 103

RENAL CLEARANCE 103

TABLE 27 MECHANISMS FOR REMOVAL OF NANOPARTICLES FROM THE BODY 104

CHAPTER 10 IN VITRO AND IN VIVO DIAGNOSTIC IMAGING 106

IN VITRO IMAGING 106

NANOPARTICLES IN DIAGNOSTIC IMAGING 106

TABLE 28 NANOPARTICLE CONTRAST MEDIA USED FOR IN VIVO DIAGNOSTIC IMAGING 107

CHAPTER 11 BIOMEDICAL NANOPARTICLE PRODUCTS 110

CURRENT FDA-APPROVED NANOPARTICLE DRUG PRODUCTS 110

TABLE 29 CURRENT FDA-APPROVED NANOPARTICLE DRUG DELIVERY SYSTEMS 110

TABLE 30 FDA-APPROVED DRUGS SPECIFICALLY FOR CANCER TREATMENT 112

TABLE 31 FDA-APPROVED DRUGS FOR CENTRAL NERVOUS SYSTEM DISEASES 113

MAJOR PLAYERS IN NANOPARTICLE DRUG DELIVERY SYSTEMS 114

MAJOR PLAYERS IN NANOPARTICLE DRUG DELIVERY SYSTEMS 114

TABLE 32 MAJOR PLAYERS IN NANOPARTICLE DRUG DEVELOPMENT AND FORMULATION

MARKET 114

COMPANY PIPELINES FOR NANOPARTICLE DRUG DELIVERY 115

TABLE 33 COMPANY PIPELINE FOR CARDIOVASCULAR NANOPARTICLE DRUGS 115

TABLE 34 COMPANY PIPELINE FOR CNS DISEASE NANOPARTICLE DRUGS 117

TABLE 35 COMPANY PIPELINE FOR GI DISEASE NANOPARTICLE DRUGS 119

TABLE 36 COMPANY PIPELINE FOR INFECTIOUS DISEASE NANOPARTICLE DRUGS 120

TABLE 37 COMPANY PIPELINE FOR CANCER NANOPARTICLE DRUGS 124

TABLE 38 COMPANY PIPELINE FOR OPHTHALMIC NANOPARTICLE DRUGS 126

TABLE 39 COMPANY PIPELINE FOR AUTOIMMUNE DISEASE NANOPARTICLE DRUGS 128

DRIVERS OF NANOPARTICLE PRODUCTS AND MARKETING 129

LIMITERS OF NANOPARTICLE PRODUCT DEVELOPMENT AND MARKETING 130

CHAPTER 12 GLOBAL MARKET FOR NANOPARTICLE DRUGS AND DELIVERY SYSTEMS 132

THE GLOBAL MARKET 132

TABLE 40 GLOBAL MARKET FOR NANOPARTICLE DRUGS AND DIAGNOSTIC IMAGING,

THROUGH 2017 ($ MILLIONS) 132

TABLE 41 GLOBAL MARKET FOR NANOPARTICLE DRUG DEVELOPMENT AND

FORMULATION AND DRUG DELIVERY SYSTEMS, THROUGH 2017 ($ MILLIONS) 133

TABLE 42 GLOBAL MARKET FOR DIAGNOSTIC IMAGING AND IN VITRO IMAGING, THROUGH

2017 ($ MILLIONS) 133

CHAPTER 13 CLINICAL TRIALS OF NANOPARTICLE DRUGS AND DRUG DELIVERY SYSTEMS 136

TABLE 43 CLINICAL TRIALS FOR NANOPARTICLE DRUGS AND DRUG DELIVERY SYSTEMS 136

TABLE 44 CLINICAL TRIALS FOR NANOPARTICLE DRUGS AND DRUG DELIVERY SYSTEMS 137

TABLE 45 CLINICAL TRIALS FOR NANOPARTICLE DRUGS AND DRUG DELIVERY SYSTEMS 140

CHAPTER 14 PATENTS, LICENSING, MERGERS AND ACQUISITIONS 143

TABLE 46 MAJOR LICENSING, COLLABORATIVE PARTNERSHIPS AND MERGER AND

ACQUISITION ACTIVITIES 143

NANOPARTICLE PATENTS 147

TABLE 47 GLOBAL PERCENTAGE SHARE OF PATENTS ISSUED BY GEOGRAPHY, FROM 2008

TO 2011 147

U.S. PATENTS FOR NANOPARTICLES DRUG DEVELOPMENT 148

TABLE 48 U.S. PATENTS FOR NANOPARTICLE DRUG DEVELOPMENT 148

U.S. PATENTS FOR NANOPARTICLE DRUG DELIVERY 148

TABLE 49 U.S. PATENTS FOR NANOPARTICLE DRUG DELIVERY 148

QUANTUM DOT PATENTS 152

TABLE 50 U.S. PATENTS FOR QUANTUM DOT TECHNOLOGY APPLIED TO MEDICAL

APPLICATIONS 152

CHAPTER 15 COMPANY PROFILES 155

ABRAXIS BIOSCIENCES, INC 155

PRODUCTS 155

STRATEGY 155

ABRAXIS PHARMACEUTICAL PRODUCTS 155

PRODUCTS 156

STRATEGY 156

ACCESS PHARMA, INC. 156

PRODUCTS 157

STRATEGY 157

ALNYLAM PHARMACEUTICALS, INC. 157

PRODUCTS 157

STRATEGY 157

AMAG PHARMACEUTICALS, INC. 158

PRODUCTS 158

STRATEGY 158

APHIOS CORPORATION 158

PRODUCTS 159

ASKLEPIOS BIOPHARMACEUTICAL, INC. 159

PRODUCTS 159

STRATEGY 160

ASTRAZENECA PHARMACEUTICALS, PLC 160

PRODUCTS 160

STRATEGY 160

BIND BIOSCIENCES, INC 160

PRODUCTS 161

STRATEGY 161

CERULEAN PHARMA INC. 161

PRODUCTS 162

STRATEGY 162

CONVATEC 162

PRODUCTS 162

STRATEGY 162

DEBIOTECH, S.A. 163

PRODUCTS 163

STRATEGY 163

ELAN PHARMACEUTICALS, INC. 163

PRODUCTS 164

STRATEGY 164

FLAMEL TECHNOLOGIES, INC 164

PRODUCTS 165

STRATEGY 165

GE GLOBAL RESEARCH 165

PRODUCTS 165

STRATEGY 166

MAGFORCE NANOTECHNOLOGIES AG 166

PRODUCTS 166

STRATEGY 166

MIV THERAPEUTICS INC. 167

PRODUCTS 167

STRATEGY 167

NANOCARRIER CO., LTD. 167

PRODUCTS 168

STRATEGY 168

NANO INTERFACE TECHNOLOGY, INC 168

PRODUCTS 168

STRATEGY 168

NANOSPHERE, INC. 169

PRODUCTS 169

STRATEGY 169

NOVARTIS INTERNATIONAL AG 169

PRODUCTS 170

STRATEGY 170

PHARMASOL CORPORATION 170

PRODUCTS 170

STRATEGY 171

SKYEPHARMA, PLC 171

PRODUCTS 171

STRATEGY 172

STARPHARMA HOLDINGS, LTD 172

PRODUCTS 172

STRATEGY 172

TALON THERAPEUTICS, INC. 173

PRODUCTS 173

STRATEGY 173

T2 BIOSYSTEMS INC. 173

PRODUCTS 174

STRATEGY 174

SUMMARY TABLE GLOBAL MARKET FOR NANOPARTICLES IN BIOTECHNOLOGY ANDPHARMACEUTICALS, THROUGH 2017 ($ MILLIONS) 6TABLE 1 DESCRIPTION OF NANOPARTICLES USED IN DRUG DELIVERY AND DIAGNOSTICIMAGING 10TABLE 2 APPLICATION OF NANOPARTICLES IN BIOTECHNOLOGY 13TABLE 3 APPLICATION OF NANOPARTICLES IN DRUG DEVELOPMENT 14TABLE 4 APPLICATION OF NANOPARTICLES IN DRUG DELIVERY SYSTEMS 15TABLE 5 NANOPARTICLE DRUG DELIVERY SYSTEMS 16TABLE 6 NANOPARTICLES USED FOR IN VIVO DIAGNOSTIC IMAGING 18TABLE 7 MAJOR PLAYERS IN NANOPARTICLE DRUG FIELD 19TABLE 8 MAJOR PLAYER COMPANY REVENUES FOR NANOPARTICLE DRUGS, THROUGH 2017($ MILLIONS) 20TABLE 9 GLOBAL MARKET FOR NANOPARTICLES IN BIOTECHNOLOGY ANDPHARMACEUTICALS, THROUGH 2017 ($ MILLIONS) 22TABLE 10 GLOBAL REVENUES BIOTECHNOLOGY APPLICATIONS OF NANOPARTICLES,THROUGH 2017 ($ MILLIONS) 23TABLE 11 GLOBAL MARKET FOR NANOPARTICLES IN DRUG DEVELOPMENT ANDFORMULATION, THROUGH 2017 ($ MILLIONS) 24TABLE 12 GLOBAL REVENUES FROM NANOPARTICLES IN DRUG DELIVERY SYSTEMS,THROUGH 2017 ($ MILLIONS) 25TABLE 13 GLOBAL REVENUES FROM NANOPARTICLES IN DIAGNOSTIC IMAGING SYSTEMS,THROUGH 2017 ($ MILLIONS) 25TABLE 14 NANOPARTICLE STRUCTURE AND PROPERTIES 28TABLE 15 SAMPLE OF DRUGS DELIVERED THROUGH LIPOSOME NANOTECHNOLOGY 39TABLE 16 APPROVED NANOCRYSTAL DRUGS 42TABLE 17 NANOPARTICLES IN BIOTECHNOLOGY APPLICATIONS 45TABLE 18 NANOBIOSENSOR TECHNOLOGY UNDER DEVELOPMENT 51TABLE 19 NANOPARTICLES IN DRUG DEVELOPMENT APPLICATIONS 53TABLE 20 MONOCLONAL ANTIBODY (MAB) DRUGS WITH POTENTIAL FOR USE INNANOPARTICLE DELIVERY SYSTEMS 54TABLE 21 SOLID LIPID NANOPARTICLE-REFORMATTED DRUGS 59TABLE 22 NANOPARTICLES IN DRUG DELIVERY APPLICATIONS 66TABLE 23 STANDARD ROUTES OF DRUG ADMINISTRATION 78TABLE 24 NANOPARTICLE TRANSDERMAL PATCH PRODUCTS 79TABLE 25 TYPES OF NANOPARTICLES SUPPLIED IN DRUG DELIVERY SYSTEMS 82TABLE 26 NANOCRYSTAL DRUGS APPROVED BY THE FDA 91TABLE 27 MECHANISMS FOR REMOVAL OF NANOPARTICLES FROM THE BODY 104TABLE 28 NANOPARTICLE CONTRAST MEDIA USED FOR IN VIVO DIAGNOSTIC IMAGING 107TABLE 29 CURRENT FDA-APPROVED NANOPARTICLE DRUG DELIVERY SYSTEMS 110TABLE 30 FDA-APPROVED DRUGS SPECIFICALLY FOR CANCER TREATMENT 112TABLE 31 FDA-APPROVED DRUGS FOR CENTRAL NERVOUS SYSTEM DISEASES 113TABLE 32 MAJOR PLAYERS IN NANOPARTICLE DRUG DEVELOPMENT AND FORMULATIONMARKET 114TABLE 33 COMPANY PIPELINE FOR CARDIOVASCULAR NANOPARTICLE DRUGS 115TABLE 34 COMPANY PIPELINE FOR CNS DISEASE NANOPARTICLE DRUGS 117TABLE 35 COMPANY PIPELINE FOR GI DISEASE NANOPARTICLE DRUGS 119TABLE 36 COMPANY PIPELINE FOR INFECTIOUS DISEASE NANOPARTICLE DRUGS 120TABLE 37 COMPANY PIPELINE FOR CANCER NANOPARTICLE DRUGS 124TABLE 38 COMPANY PIPELINE FOR OPHTHALMIC NANOPARTICLE DRUGS 126TABLE 39 COMPANY PIPELINE FOR AUTOIMMUNE DISEASE NANOPARTICLE DRUGS 128TABLE 40 GLOBAL MARKET FOR NANOPARTICLE DRUGS AND DIAGNOSTIC IMAGING,THROUGH 2017 ($ MILLIONS) 132TABLE 41 GLOBAL MARKET FOR NANOPARTICLE DRUG DEVELOPMENT AND FORMULATIONAND DRUG DELIVERY SYSTEMS, THROUGH 2017 ($ MILLIONS) 133TABLE 42 GLOBAL MARKET FOR DIAGNOSTIC IMAGING AND IN VITRO IMAGING, THROUGH2017 ($ MILLIONS) 133TABLE 43 CLINICAL TRIALS FOR NANOPARTICLE DRUGS AND DRUG DELIVERY SYSTEMS 136TABLE 44 CLINICAL TRIALS FOR NANOPARTICLE DRUGS AND DRUG DELIVERY SYSTEMS 137TABLE 45 CLINICAL TRIALS FOR NANOPARTICLE DRUGS AND DRUG DELIVERY SYSTEMS 140TABLE 46 MAJOR LICENSING, COLLABORATIVE PARTNERSHIPS AND MERGER ANDACQUISITION ACTIVITIES 143TABLE 47 GLOBAL PERCENTAGE SHARE OF PATENTS ISSUED BY GEOGRAPHY, FROM 2008TO 2011 147TABLE 48 U.S. PATENTS FOR NANOPARTICLE DRUG DEVELOPMENT 148TABLE 49 U.S. PATENTS FOR NANOPARTICLE DRUG DELIVERY 148TABLE 50 U.S. PATENTS FOR QUANTUM DOT TECHNOLOGY APPLIED TO MEDICALAPPLICATIONS 152

LIST OF FIGURES

SUMMARY FIGURE GLOBAL MARKET FOR NANOPARTICLES IN BIOTECHNOLOGY AND

PHARMACEUTICALS, 2010-2017 ($ MILLIONS) 7

__________________________

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker